Deals this week: Zebra Biologics, Mount Tam Biotechnologies, Adynxx
Zebra Biologics and AbbVie have signed an agreement to jointly discover agonist antibody therapeutics for inflammatory diseases using the former’s function-based antibody discovery platform.
Pre-clinical emerging antibody candidates that activate biological pathways associated with targets designated by AbbVie will be identified and evaluated on the platform.
Ferring International Center’s subsidiary Mount Tam Biotechnologies has signed an agreement with bio-pharmaceutical company Isomerase Therapeutics.
Under the agreement, the two US-based companies will discover and develop novel and improved rapalogs.
US chronic pain therapeutics developer Adynxx has raised $16m in series B financing, which will be utilised to fund the continued development of its AYX1 programme.
The programme aims to develop therapeutics for the reduction of acute pain and prevention of chronic pain following surgery.
TPG Biotech and Domain Associates led the financing.
German biopharmaceutical company Eternygen has announced a series A financing round to raise €8m ($8.4m), which will be used to accelerate its small molecule NaCT inhibitors towards the selection of a pre-clinical lead candidate.
The financing round was led by Epidarex Capital in participation with Evotec AG and VC Fonds Technologie Berlin.
Celgene Switzerland, an affiliate of US-based biopharmaceutical company Celgene Corporation, has signed an exclusive global research agreement with Anokion, a bio-pharmaceutical company based in Switzerland.
The agreement enables the development of novel tolerance-inducing therapies for autoimmune diseases.
Anokion has received a $45m upfront payment and will receive a further $10m depending on the achievement of certain pre-clinical development milestones, while Celgene has obtained an equity interest in Anokion.
Furthermore, the agreement gives Celgene exclusive right to acquire Anokion at pre-specified exercise points.
myTomorrows, a provider of drugs in development to physicians and patients in need, has raised €10m ($10.53m) in a venture financing round led by EQT Ventures and Octopus Ventures.
Existing investors Balderton Capital (UK) and Sofinnova Partners SAS have also participated in the round.
The funds are intended to be utilised to provide physicians and patients with improved access to drugs in development.
US-based Bayer Corporation has signed a collaboration agreement with the University of Pittsburgh to advance research in order to develop new therapeutics for heart, lung and blood disease indications.
Under the agreement, Bayer will also support independent investigators performing clinical trial in sickle-cell disease.
US-based biopharmaceutical company Sarepta Therapeutics and Nationwide Children's Hospital have signed a research and option agreement.
Under the agreement, the former will support the clinical development of the latter’s microdystrophin gene therapy programme, which targets Duchenne muscular dystrophy.
The agreement also gives Sarepta an exclusive option to license the programme.
Karolinska Institutet has agreed to assist NeuroVive Pharmaceutical in the development of NV556, a cyclophilin D inhibitor compound targeting mitochondrial myopathy.
A team led by one of the institute’s professors, Hakan Westerblad, will study the compound and its effects in experimental models of mitochondrial myopathy.
Merck KGaA and Aduro BioTech have agreed to investigate the latter’s immunotherapy CRS-207 in combination with the former’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for the treatment of gastric cancer.